Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxUPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Clinical Trial: JSB462 (Luxdegalutamide) in Combination With Abiraterone for mHSPC
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026